Factor XIIIA-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking.
Alessandro PorrelloPatrick L LeslieEmily B HarrisonBalachandra K GorentlaSravya KattulaSubrata K GhoshSalma H AzamAlisha HoltzhausenYvonne L ChaoMichele C HaywardTrent A WaughSanggyu BaeVirginia GodfreyScott H RandellCecilia OderupLiza MakowskiJared WeissMatthew D WilkersonD Neil HayesH Shelton EarpAlbert S BaldwinAlisa S WolbergChad V PecotPublished in: Nature communications (2018)
Lung cancer is the leading cause of cancer-related deaths worldwide, and lung squamous carcinomas (LUSC) represent about 30% of cases. Molecular aberrations in lung adenocarcinomas have allowed for effective targeted treatments, but corresponding therapeutic advances in LUSC have not materialized. However, immune checkpoint inhibitors in sub-populations of LUSC patients have led to exciting responses. Using computational analyses of The Cancer Genome Atlas, we identified a subset of LUSC tumors characterized by dense infiltration of inflammatory monocytes (IMs) and poor survival. With novel, immunocompetent metastasis models, we demonstrated that tumor cell derived CCL2-mediated recruitment of IMs is necessary and sufficient for LUSC metastasis. Pharmacologic inhibition of IM recruitment had substantial anti-metastatic effects. Notably, we show that IMs highly express Factor XIIIA, which promotes fibrin cross-linking to create a scaffold for LUSC cell invasion and metastases. Consistently, human LUSC samples containing extensive cross-linked fibrin in the microenvironment correlated with poor survival.
Keyphrases
- papillary thyroid
- high grade
- squamous cell
- end stage renal disease
- squamous cell carcinoma
- oxidative stress
- small cell lung cancer
- newly diagnosed
- stem cells
- dendritic cells
- low grade
- chronic kidney disease
- ejection fraction
- peripheral blood
- prognostic factors
- free survival
- single cell
- immune response
- peritoneal dialysis
- genome wide
- lymph node metastasis
- young adults
- dna methylation
- liver injury
- cancer therapy
- drug induced